Loading...
Symbols:
Loading...
Symbols:
Forest Laboratories Inc. (FRX)
|
|
|
| 52wk high: | |
| 52wk low: | |
| EPS: | |
| PE: | |
| Dividend: | |
| Yield: | |
| Market Cap: | |
| Exchange: |
Articles on Forest Laboratories Inc. (FRX)
43 articles
Filter by:
Latest Articles Most commented on articlesMost frequent authors on FRX
- Mike Havrilla(9)
- Andrew Wilkinson(4)
- SA Editor Eli Hoffmann(3)
- Davy Bui(2)
- Aaron F. Barkoff(2)
Most popular authors
(tracked in watchlists)
- Philip Davis(587)
- Bespoke Investment Group(571)
- Trader Mark(488)
- SA Editor Eli Hoffmann(386)
- Andrew Wilkinson(332)
Most commented on authors
- SA Editor Eli Hoffmann(26)
- Keith Robison(11)
- Andrew Mickey(8)
- Mike Havrilla(8)
- SA Editor Joan Wickham(7)
- Sell Risk, Buy Pharma
- What Are Some of the Best Hedge Fund Managers Doing?
- Berkowitz, Rodriguez and Pabrai: Examining Q3 Filings
- Recessionary Equity Strategies: Having It All
- Backlog of Decisions Is Building at the FDA
- Six Healthcare Stocks at Sale Prices
- Recessionary Equity Strategies: Flight to Quality
- FDA Action Before Year End
- Options Trader: Outlook for a Testy Tuesday
- Where's the Smartest Money Investing?
- Potential Short Trades on Pending FDA Decisions
- Cypress Bioscience Could Be a Buy Given Upcoming FDA Decision
- Pharmaceuticals: Near Term Movers Based On FDA Decision Dates
- FDA Fall Decision Calendar Features Some Likely Near-Term Movers
- Is Cypress Bioscience Poised to Move Ahead?
- Wednesday Options Outlook: EP, FTO, XLE, YHOO, FRX, EWZ, ETH, ACN
- 2008 Q2 Portfolio Holdings: Berkowitz, Rodriguez & Pabrai
- Time to Invest in Pharmaceuticals?
- Thursday Options Outlook: WPI, ADSK, DNA, NITE, LEN, CTRP, FRX, IDCC
- Friday Options Outlook: GFI, GDX, FRX, BP, CPN, ITMN, S
- Wall Street Breakfast: Must-Know News
- Earnings Preview: Forest Laboratories
- Cypress Bioscience Awaits Two Key Catalysts
- 10 Pharmaceutical Stocks and Their Patent Expiration Drugs
- Wyeth's Alzheimer's Vaccine Could Become World's #1 Drug - Barron's
- Federal Circuit Rules in Favor of Forest in Dispute with Caraco over Lexapro
- Pfizer Should Buy Amgen or Wyeth - Credit Suisse
- Notable Earnings Reports in an Interesting and Painful Market
- Under The Radar News - Monday
- AmTech's Top Stock Ideas for 2008
- Twelve Large Cap Stock Picks
- Federal Circuit Court Denies Teva's Appeal of Forest Labs' Lexapro Patent
- Forest Labs' Rights Affirmed in Lexapro Appeal
- Cash-Rich Companies: Watch Out for the Siren’s Song
- Daily Options Report: Lyondell, Charter, Nautilus, Novellus, Coke and ETFs
- Today's Analyst Actions: YUM, NYX, CME, FRX, VMC Upgraded, HAL, BHI, BJS, CPB Downgraded
- Forest Labs On the Rebound: How Long Will These Strong Profits Last?
- Forest Labs: Antidepressant Drug Lexapro Maintains Market Share
- Biotech Stocks Day-in-Review: IPOs Heat Up
- Forest Labs Ups 2007 Estimates
- Most Extended S&P 500 Stocks
Hedge Fund Jobs
Job Seekers: Search jobs by category, get job alerts by email or live feed, apply online See full list of jobs »
Employers: See all recruitment options, get applications online or by email Post a job »